Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer

Completed · Phase 1/Phase 2

Conditions studied: Metastatic Prostate Cancer

In brief

This research is being done to see if an investigational radioactive drug called 18F-DCFBC can help us find cancer that has spread (metastatic disease) from its original site in people who have cancer in their prostate to other parts of their body.

Key facts

Study ID

NCT01815515

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

22

Starts

2013-03-01

Expected to finish

2015-11-18

Last updated by the study team

2018-08-20

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histological confirmation of prostate cancer
• Radiologic evidence of new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), bone scintigraphy, [18F]Sodium Fluoride PET, and/or [18F]FDG PET
• Rising PSA on two observations taken at least 1 week apart
• Adequate peripheral venous access or available central venous catheter access for radiopharmaceutical administration
• Patient can remain on androgen deprivation therapy if on the same regimen prior to documentation of progressive metastatic disease
• Patient cannot start a new therapy for prostate cancer prior to study radiopharmaceutical imaging
• Patient is judged by the Investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits
• Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures

You may not qualify if…

• Patient has been treated with an investigational drug, investigational biologic, or investigational therapeutic device within 14 days prior to study radiotracer administration
• Prior radiation therapy, chemotherapy, or androgen-deprivation therapy within 2 weeks prior to study radiotracer administration (Washout is one half-life of the drug or 2 weeks, whichever is longest)
• Initiation of new therapy for progressive metastatic disease since radiographic documentation of progression.
• Serum creatinine > 3 times the upper limit of normal
• Total bilirubin > 3 times the upper limit of normal
• Liver Transaminases > 5times the upper limit of normal
• Unable to lie flat during or tolerate PET/CT
• Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.

Where it is running

• Johns Hopkins University — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.